FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079408175> ?p ?o ?g. }

• W2079408175 endingPage "312" @default.
• W2079408175 startingPage "307" @default.
• W2079408175 abstract "The high-density lipoprotein (HDL)-Atherosclerosis Treatment Study showed that simvastatin plus niacin (mean daily dose 13 mg and 2.4 g, respectively) halt angiographic atherosclerosis progression and reduce major clinical events by 60% in patients with coronary artery disease (CAD) who have low HDL, in comparison with placebos, over 3 years. How safe and well-tolerated is this combination? One hundred sixty patients with CAD, including 25 with diabetes mellitus, with mean low-density lipoprotein cholesterol of 128 mg/dl, HDL cholesterol of ≤35 mg/dl (mean 31), and mean triglycerides of 217 mg/dl were randomized to 4 factorial combinations of antioxidant vitamins or their placebos and simvastatin plus niacin or their placebos. Patients were examined monthly or bimonthly for 38 months; side effects (gastrointestinal upset, nausea, anorexia, vision, skin, and energy problems, or muscle aches) were directly queried and recorded. Aspartate aminotransferase, creatine phosphokinase (CPK), uric acid, homocysteine, and fasting glucose levels were regularly monitored. A safety monitor reviewed all side effects and adjusted drug dosages accordingly. Patients who received simvastatin plus niacin and those on placebo had similar frequencies of clinical or laboratory side effects: any degree of flushing (30% vs 23%, p = NS), symptoms of fatigue, nausea, and/or muscle aches (9% vs 5%, p = NS), aspartate aminotransferase (SGOT) ≥3 times upper limit of normal (3% vs 1%, p = NS), CPK ≥2 times upper limit of normal (3% vs 4%, p = NS), CPK ≥5 times upper limit of normal, new onset of uric acid ≥7.5 mg/dl (18% vs 15%, p = NS), and homocysteine ≥15 μmol/L (9% vs 4%, p = NS). Glycemic control among diabetics declined mildly in the simvastatin-niacin group but returned to pretreatment levels at 8 months and remained stable for rest of the study. This combination regimen was repeatedly described by 91% of treated patients and 86% of placebo subjects as “very easy” or “fairly easy” to take. Thus, the simvastatin plus niacin regimen is effective, safe, and well tolerated in patients with or without diabetes mellitus." @default.
• W2079408175 created "2016-06-24" @default.
• W2079408175 creator A5019882573 @default.
• W2079408175 creator A5020239292 @default.
• W2079408175 creator A5022745436 @default.
• W2079408175 creator A5042195689 @default.
• W2079408175 creator A5056498062 @default.
• W2079408175 creator A5064676461 @default.
• W2079408175 creator A5073954913 @default.
• W2079408175 creator A5074124714 @default.
• W2079408175 creator A5088942144 @default.
• W2079408175 date "2004-02-01" @default.
• W2079408175 modified "2023-10-05" @default.
• W2079408175 title "Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)" @default.
• W2079408175 cites W1988179941 @default.
• W2079408175 cites W2001923460 @default.
• W2079408175 cites W2009502206 @default.
• W2079408175 cites W2010047125 @default.
• W2079408175 cites W2027754732 @default.
• W2079408175 cites W2028737910 @default.
• W2079408175 cites W2033321161 @default.
• W2079408175 cites W2046991199 @default.
• W2079408175 cites W2059839825 @default.
• W2079408175 cites W2061716149 @default.
• W2079408175 cites W2070855777 @default.
• W2079408175 cites W2113434143 @default.
• W2079408175 cites W2119065130 @default.
• W2079408175 cites W2150968881 @default.
• W2079408175 cites W2160689800 @default.
• W2079408175 cites W2164573667 @default.
• W2079408175 cites W2418611981 @default.
• W2079408175 cites W2725187802 @default.
• W2079408175 cites W2975364463 @default.
• W2079408175 cites W4238251256 @default.
• W2079408175 cites W4249750268 @default.
• W2079408175 doi "https://doi.org/10.1016/j.amjcard.2003.10.009" @default.
• W2079408175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14759379" @default.
• W2079408175 hasPublicationYear "2004" @default.
• W2079408175 type Work @default.
• W2079408175 sameAs 2079408175 @default.
• W2079408175 citedByCount "108" @default.
• W2079408175 countsByYear W20794081752012 @default.
• W2079408175 countsByYear W20794081752013 @default.
• W2079408175 countsByYear W20794081752014 @default.
• W2079408175 countsByYear W20794081752015 @default.
• W2079408175 countsByYear W20794081752016 @default.
• W2079408175 countsByYear W20794081752017 @default.
• W2079408175 countsByYear W20794081752018 @default.
• W2079408175 countsByYear W20794081752020 @default.
• W2079408175 countsByYear W20794081752022 @default.
• W2079408175 crossrefType "journal-article" @default.
• W2079408175 hasAuthorship W2079408175A5019882573 @default.
• W2079408175 hasAuthorship W2079408175A5020239292 @default.
• W2079408175 hasAuthorship W2079408175A5022745436 @default.
• W2079408175 hasAuthorship W2079408175A5042195689 @default.
• W2079408175 hasAuthorship W2079408175A5056498062 @default.
• W2079408175 hasAuthorship W2079408175A5064676461 @default.
• W2079408175 hasAuthorship W2079408175A5073954913 @default.
• W2079408175 hasAuthorship W2079408175A5074124714 @default.
• W2079408175 hasAuthorship W2079408175A5088942144 @default.
• W2079408175 hasConcept C126322002 @default.
• W2079408175 hasConcept C134018914 @default.
• W2079408175 hasConcept C142724271 @default.
• W2079408175 hasConcept C197934379 @default.
• W2079408175 hasConcept C204787440 @default.
• W2079408175 hasConcept C27081682 @default.
• W2079408175 hasConcept C2776329913 @default.
• W2079408175 hasConcept C2778163477 @default.
• W2079408175 hasConcept C2778213512 @default.
• W2079408175 hasConcept C2778375690 @default.
• W2079408175 hasConcept C2779881121 @default.
• W2079408175 hasConcept C2780092750 @default.
• W2079408175 hasConcept C2780580376 @default.
• W2079408175 hasConcept C71924100 @default.
• W2079408175 hasConcept C90924648 @default.
• W2079408175 hasConceptScore W2079408175C126322002 @default.
• W2079408175 hasConceptScore W2079408175C134018914 @default.
• W2079408175 hasConceptScore W2079408175C142724271 @default.
• W2079408175 hasConceptScore W2079408175C197934379 @default.
• W2079408175 hasConceptScore W2079408175C204787440 @default.
• W2079408175 hasConceptScore W2079408175C27081682 @default.
• W2079408175 hasConceptScore W2079408175C2776329913 @default.
• W2079408175 hasConceptScore W2079408175C2778163477 @default.
• W2079408175 hasConceptScore W2079408175C2778213512 @default.
• W2079408175 hasConceptScore W2079408175C2778375690 @default.
• W2079408175 hasConceptScore W2079408175C2779881121 @default.
• W2079408175 hasConceptScore W2079408175C2780092750 @default.
• W2079408175 hasConceptScore W2079408175C2780580376 @default.
• W2079408175 hasConceptScore W2079408175C71924100 @default.
• W2079408175 hasConceptScore W2079408175C90924648 @default.
• W2079408175 hasIssue "3" @default.
• W2079408175 hasLocation W20794081751 @default.
• W2079408175 hasLocation W20794081752 @default.
• W2079408175 hasOpenAccess W2079408175 @default.
• W2079408175 hasPrimaryLocation W20794081751 @default.
• W2079408175 hasRelatedWork W1265589548 @default.
• W2079408175 hasRelatedWork W1974808961 @default.
• W2079408175 hasRelatedWork W1985181099 @default.

• next